⌕
Iambic Therapeutics · IAM · Nasdaq
$13.10at last closeTenet — · insufficient data
Compare
$13.10at last close

Iambic Therapeutics (IAM) Stock

Industry: Biological Products, Except Diagnostic Substances · see every company filed here →

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetHow we compute thisNot investment advice

Iambic Therapeutics, Inc. isn't scored yet Not enough ingested fundamentals to compute a Tenet Score for this stock.

Tenet Score

Not scored. We do not hold normalized financials for this listing, so the Tenet value screens do not apply. That is usually a foreign-domiciled ADR or a very new listing. Its price, chart, and news below are its own.

Price

Loading chart…
P/E
—
no P/E on file
P/B
—
no P/B on file
P/S
—
no P/S on file
ROE
—
no ROE for this year, and Tenet does not compute one yet
Operating margin
—
no operating margin on file
Net margin
—
no net margin on file
Current ratio
—
no current ratio on file
Net debt / EBITDA
—
no leverage ratio on file
EPS CAGR 5y
—
needs five years of positive earnings
Market cap
$122.8M
small cap
Div yield
—
no yield on file
52-wk range
9.60 – 25.00
low → high, since listing

Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).

The rest of this report

Which sections of this report have data for this listing, and a live peek at each.
About Iambic Therapeutics, Inc.

We are a technology and clinical-stage life sciences company pursuing a fundamental shift in the biopharmaceutical industry. Our mission is to make better technology for better medicines. We do this by integrating leading proprietary, large-scale artificial…

Not investment advice.

ETF exposure

held by 2 US ETFs · top wrappers by weightSee all ETFs holding IAM →

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.